Ocular Proteomics Testing In Chronic Atrophy

NCT07298291 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-05-01

No results posted yet for this study

Summary

Study to evaluate the safety of routine diagnostic anterior chamber paracentesis (ACP) for proteomic profiling in patients with geographic atrophy (GA)

Conditions

  • Age-Related (Dry) Macular Degeneration

Interventions

PROCEDURE

AC Tap (anterior chamber paracenthesis)

anterior chamber paracenthesis (microvolume of eye fluid is taken)

Sponsors & Collaborators

  • ClinOmicsAI

    lead NETWORK

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-30
Primary Completion
2026-07-30
Completion
2026-12-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07298291 on ClinicalTrials.gov